Mellinghoff IK - Search Results

1

AKT activity determines sensitivity to mammalian target of rapamycin (mTOR) inhibitors by regulating cyclin D1 and c-myc expression.

Gera JF, Mellinghoff IK, Shi Y, Rettig MB, Tran C, Hsu JH, Sawyers CL, Lichtenstein AK. Gera JF, et al. Among authors: mellinghoff ik. J Biol Chem. 2004 Jan 23;279(4):2737-46. doi: 10.1074/jbc.M309999200. Epub 2003 Oct 23. J Biol Chem. 2004. PMID: 14576155 Free article.

2

Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR.

Neshat MS, Mellinghoff IK, Tran C, Stiles B, Thomas G, Petersen R, Frost P, Gibbons JJ, Wu H, Sawyers CL. Neshat MS, et al. Among authors: mellinghoff ik. Proc Natl Acad Sci U S A. 2001 Aug 28;98(18):10314-9. doi: 10.1073/pnas.171076798. Epub 2001 Aug 14. Proc Natl Acad Sci U S A. 2001. PMID: 11504908 Free PMC article.

3

The emergence of resistance to targeted cancer therapeutics.

Mellinghoff IK, Sawyers CL. Mellinghoff IK, et al. Pharmacogenomics. 2002 Sep;3(5):603-23. doi: 10.1517/14622416.3.5.603. Pharmacogenomics. 2002. PMID: 12223047 Review.

4

Growth inhibitory effects of the dual ErbB1/ErbB2 tyrosine kinase inhibitor PKI-166 on human prostate cancer xenografts.

Mellinghoff IK, Tran C, Sawyers CL. Mellinghoff IK, et al. Cancer Res. 2002 Sep 15;62(18):5254-9. Cancer Res. 2002. PMID: 12234993

5

TORward AKTually useful mouse models.

Mellinghoff IK, Sawyers CL. Mellinghoff IK, et al. Nat Med. 2004 Jun;10(6):579-80. doi: 10.1038/nm0604-579. Nat Med. 2004. PMID: 15170198 No abstract available.

6

HER2/neu kinase-dependent modulation of androgen receptor function through effects on DNA binding and stability.

Mellinghoff IK, Vivanco I, Kwon A, Tran C, Wongvipat J, Sawyers CL. Mellinghoff IK, et al. Cancer Cell. 2004 Nov;6(5):517-27. doi: 10.1016/j.ccr.2004.09.031. Cancer Cell. 2004. PMID: 15542435 Free article.

7

Monitoring antiproliferative responses to kinase inhibitor therapy in mice with 3'-deoxy-3'-18F-fluorothymidine PET.

Waldherr C, Mellinghoff IK, Tran C, Halpern BS, Rozengurt N, Safaei A, Weber WA, Stout D, Satyamurthy N, Barrio J, Phelps ME, Silverman DH, Sawyers CL, Czernin J. Waldherr C, et al. Among authors: mellinghoff ik. J Nucl Med. 2005 Jan;46(1):114-20. J Nucl Med. 2005. PMID: 15632041 Free article.

8

Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors.

Mellinghoff IK, Wang MY, Vivanco I, Haas-Kogan DA, Zhu S, Dia EQ, Lu KV, Yoshimoto K, Huang JH, Chute DJ, Riggs BL, Horvath S, Liau LM, Cavenee WK, Rao PN, Beroukhim R, Peck TC, Lee JC, Sellers WR, Stokoe D, Prados M, Cloughesy TF, Sawyers CL, Mischel PS. Mellinghoff IK, et al. N Engl J Med. 2005 Nov 10;353(19):2012-24. doi: 10.1056/NEJMoa051918. N Engl J Med. 2005. PMID: 16282176 Free article.

9

Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer.

Thomas GV, Tran C, Mellinghoff IK, Welsbie DS, Chan E, Fueger B, Czernin J, Sawyers CL. Thomas GV, et al. Among authors: mellinghoff ik. Nat Med. 2006 Jan;12(1):122-7. doi: 10.1038/nm1337. Epub 2005 Dec 11. Nat Med. 2006. PMID: 16341243

10

Mammalian target of rapamycin inhibition promotes response to epidermal growth factor receptor kinase inhibitors in PTEN-deficient and PTEN-intact glioblastoma cells.

Wang MY, Lu KV, Zhu S, Dia EQ, Vivanco I, Shackleford GM, Cavenee WK, Mellinghoff IK, Cloughesy TF, Sawyers CL, Mischel PS. Wang MY, et al. Among authors: mellinghoff ik. Cancer Res. 2006 Aug 15;66(16):7864-9. doi: 10.1158/0008-5472.CAN-04-4392. Cancer Res. 2006. PMID: 16912159

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

154 results

Search Page

Filters